Fractional Flow Reserve–Guided PCI or Coronary Bypass Surgery for 3-Vessel Coronary Artery Disease: 3-Year Follow-Up of the FAME 3 Trial
Circulation · 19.09.2023 · 148 (12) · 950-958
DOI: 10.1161/circulationaha.123.065770 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Circulation, erschienen am 19.09.2023. Verfasst von Frederik M Zimmermann und 38 weiteren Autor:innen. Beteiligte Einrichtung: Catharina Hospital, Eindhoven, the Netherlands (F.M.Z., N.H.J.P., A.H.M.v.S., P.A.L.T.). Hauptthemen laut MEDLINE: Coronary Artery Disease, Fractional Flow Reserve, Myocardial, Percutaneous Coronary Intervention, Myocardial Infarction. Die Arbeit wurde bisher 62-mal zitiert (Crossref) und nennt 25 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Previous studies comparing percutaneous coronary intervention (PCI) with coronary artery bypass grafting (CABG) in patients with multivessel coronary disease not involving the left main have shown significantly lower rates of death, myocardial infarction (MI), or stroke after CABG. These studies did not routinely use current-generation drug-eluting stents or fractional flow reserve (FFR) to guide PCI. METHODS: FAME 3 (Fractional Flow Reserve versus Angiography for Multivessel Evaluation) is an investigator-initiated, multicenter, international, randomized trial involving patients with 3-vessel coronary artery disease (not involving the left main coronary artery) in 48 centers worldwide. Patients were randomly assigned to receive FFR-guided PCI using zotarolimus drug-eluting stents or CABG. The prespecified key secondary end point of the trial reported here is the 3-year incidence of the composite of death, MI, or stroke. RESULTS: A total of 1500 patients were randomized to FFR-guided PCI or CABG. Follow-up was achieved in >96% of patients in both groups. There was no difference in the incidence of the composite of death, MI, or stroke after FFR-guided PCI compared with CABG (12.0% versus 9.2%; hazard ratio [HR], 1.3 [95% CI, 0.98–1.83]; P =0.07). The rates of death (4.1% versus 3.9%; HR, 1.0 [95% CI, 0.6–1.7]; P =0.88) and stroke (1.6% versus 2.0%; HR, 0.8 [95% CI, 0.4–1.7]; P =0.56) were not different. MI occurred more frequently after PCI (7.0% versus 4.2%; HR, 1.7 [95% CI, 1.1–2.7]; P =0.02). CONCLUSIONS: At 3-year follow-up, there was no difference in the incidence of the composite of death, MI, or stroke after FFR-guided PCI with current-generation drug-eluting stents compared with CABG. There was a higher incidence of MI after PCI compared with CABG, with no difference in death or stroke. These results provide contemporary data to allow improved shared decision-making between physicians and patients with 3-vessel coronary artery disease. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02100722.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Catharina Hospital, Eindhoven, the Netherlands (F.M.Z., N.H.J.P., A.H.M.v.S., P.A.L.T.).
- Quantitative Sciences Unit (V.Y.D., M.D.), Stanford University, CA.
- Gottsegen National Cardiovascular Center, Hungary (Z.P., L.S.).
- Clinic of Cardiac and Vascular Diseases, Institute of Clinical Medicine, Vilnius University, Lithuania (G.D., G.K.).
- Vilnius University Hospital Santaros Klinikos, Lithuania (G.D., G.K.).
- Centre Hospitalier de l'Université de Montréal, Canada (S.M.).
ORCID-Profile: Victoria Y Ding, Zsolt Piroth, Albert H M van Straten, Laszlo Szekely, Rajesh Kharbanda, Adel Aminian, Keith G Oldroyd, Petr Kala, Filip Casselman, Kreton Mavromatis, Steven E S Miner, Evald H Christiansen, Michael J Reardon, Yuhei Kobayashi, Mark A Hlatky, Kenneth W Mahaffey, Manisha Desai, Y Joseph Woo, Bernard De Bruyne, William F Fearon
Zitieren
APA
Zimmermann, F. M., Ding, V. Y., Pijls, N. H. J., Piroth, Z., van Straten, A. H. M., Szekely, L., Davidavicius, G., Kalinauskas, G., Mansour, S., Kharbanda, R., Östlund-Papadogeorgos, N., Aminian, A., Oldroyd, K. G., Al-Attar, N., Jagic, N., Dambrink, J. E., Kala, P., Angeras, O., MacCarthy, P., …, & FAME 3 Investigators (2023). Fractional Flow Reserve–Guided PCI or Coronary Bypass Surgery for 3-Vessel Coronary Artery Disease: 3-Year Follow-Up of the FAME 3 Trial. Circulation, 148(12), 950-958. https://doi.org/10.1161/circulationaha.123.065770
Vancouver
Zimmermann FM, Ding VY, Pijls NHJ, Piroth Z, van Straten AHM, Szekely L, et al. Fractional Flow Reserve–Guided PCI or Coronary Bypass Surgery for 3-Vessel Coronary Artery Disease: 3-Year Follow-Up of the FAME 3 Trial. Circulation. 2023;148(12):950-958. doi:10.1161/circulationaha.123.065770
BibTeX
@article{Zimmermann2023,
author = {Zimmermann, Frederik M and Ding, Victoria Y and Pijls, Nico H J and Piroth, Zsolt and van Straten, Albert H M and Szekely, Laszlo and Davidavicius, Giedrius and Kalinauskas, Gintaras and Mansour, Samer and Kharbanda, Rajesh and Östlund-Papadogeorgos, Nikolaos and Aminian, Adel and Oldroyd, Keith G and Al-Attar, Nawwar and Jagic, Nikola and Dambrink, Jan-Henk E and Kala, Petr and Angeras, Oskar and MacCarthy, Philip and Wendler, Olaf and Casselman, Filip and Witt, Nils and Mavromatis, Kreton and Miner, Steven E S and Sarma, Jaydeep and Engstrøm, Thomas and Christiansen, Evald H and Tonino, Pim A L and Reardon, Michael J and Otsuki, Hisao and Kobayashi, Yuhei and Hlatky, Mark A and Mahaffey, Kenneth W and Desai, Manisha and Woo, Y Joseph and Yeung, Alan C and De Bruyne, Bernard and Fearon, William F and FAME 3 Investigators, FAME 3 Investigators},
title = {Fractional Flow Reserve–Guided PCI or Coronary Bypass Surgery for 3-Vessel Coronary Artery Disease: 3-Year Follow-Up of the FAME 3 Trial},
journal = {Circulation},
year = {2023},
volume = {148},
number = {12},
pages = {950--958},
doi = {10.1161/circulationaha.123.065770}
}
EUVIMED